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Abstract. 
 
Aims: to debate current understandings about the psychobiological effects of recreational 
MDMA or ‘ecstasy’, and recommend theoretically-driven topics for future research.   
Methods: recent empirical findings, especially those from novel topic areas were reviewed. 
Potential causes for the high variance often found in group findings were also examined.  
Results and conclusions: the first empirical reports into psychobiological and psychiatric 
aspects from the early 1990s concluded that regular users demonstrated some selective 
psychobiological deficits, for instance worse declarative memory, or heightened depression. 
More recent research has covered a far wider range of psychobiological functions, and deficits 
have emerged in aspects of vision, higher cognitive skill, neurohormonal functioning, and 
foetal developmental outcomes, and other. However, variance levels are often high, indicating 
that while while that some recreational users develop problems, others are less affected. 
Potential reasons for this high variance are debated. An explanatory model based on multi-
factorial causation is then proposed.  
Future directions:  a number of theoretically driven research topics are suggested, in order to 
empirically investigate the potential causes for these diverse psychobiological deficits. Future 
neuroimaging studies should study the practical implications of any serotonergic and/or 
neurohormonal changes, using a wide range of functional measures. 
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Introduction. 
 
The recreational use of 3,4-methylenedioxymethamphetamine (MDMA) commenced 
primarily during the mid-1980s, and the first empirical reports on its physiological, 
psychobiological, and psychiatric aspects were published within a few years (Shulgin, 1986; 
Peroutka, 1989; McCann and Ricaurte, 1991). These were complemented by early cohort 
studies (Peroutka et al, 1988; Solowij et al, 1990; Krystal et al, 1992), and since then 
numerous empirical investigations have been conducted. The emergent findings have been the 
focus for a number of reviews (McCann and Ricaurte, 2000; 2014; Parrott, 2001, 2006, 
2013a; Rogers et al, 2009; White 2014). These reviews have shown that recreational users can 
display a range of psychobiological deficits, while other psychobiological functions may 
remain intact. The first areas of deficit to be described included aspects of memory and 
cognition, sleep, and certain psychiatric disorders such as depression (McCann and Ricaurte, 
1991; Curran and Travill, 1997; Schifano et al, 1998; Parrott et al, 1998; McGuire,  2000; 
Wareing, et al, 2000; Verkes, et al., 2001; Soar et al, 2001; McCardle et al, 2004).  
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Subsequent research investigated a wider range of psychobiological functions, and several 
further areas of deficits have been identified. They have included vision, higher cognition, 
psychomotor performance, neurohormonal activity, immunocompetance,  and its effects when 
taken by pregnant women on birth outcomes and subsequent child development (Gerra et al, 
2003; Fisk, et al., 2005; Murray et al, 2012; Parrott, 2013b; Singer et al, 2012a,b, 2016). One 
aim of this current perspective paper is to summarise the wider range of problems revealed by 
this expansion in research.  
 
As with many of the earlier studies into the psychobiological effects of MDMA consumption, 
these more recent investigations have described an intriguing mixture of significant and non-
significant findings. This is certainly apparent in neurocognition research, particularly in the 
area of executive functioning. While some studies report ecstasy-related cognitive 
dysfunctions, other studies report intact task performance (Murphy et al, 2009; Roberts et al, 
2016a). Furthermore, even when a single cognitive measure is used, deficits are apparent in 
some studies - but not in others (Rogers et al, 2009). This variation also occurs with vision 
research, since while some visual skills remain unaffected, other visual tasks demonstrate 
significant impairments (Murray et al, 2012). Similarly with sleep studies, some individuals 
report impairments - whereas others do not (McCann et al, 2007, 2009; Ogeil et al, 2011, 
2013). In neurohormonal research, while overall group cortisol levels are significantly raised, 
the MDMA subgroup data often shows pronounced variance, which again indicates 
considerable variation in drug effects between individuals (see Figure 1 in Parrott et al, 2014). 
It is important that this variance in physical and psychological findings is incorporated into 
our models of causation. Hence, this current perspective will debate the factors which may 
influence the development or non-development of neuropsychobiological problems in 
recreational Ecstasy/MDMA users. It will also  suggestalso suggest some future research 
topics with a theoretical rationale for examining the causes of this variation.  
 
Neurocognition    
 
The first area of psychobiological deficit to be associated with MDMA usage was 
declarative memory (Krystal et al, 1993). Many subsequent studies have empirically 
confirmed the presence of memory deficits in some Ecstasy/MDMA users, although 
as noted earlier, a degree of variation has also been apparent (Laws and Kokkalis, 
2007; Rogers et al, 2009). Many studies have also observed that prospective memory 
is impaired in MDMA users; with damage to 5-HT rich areas in the hippocampal and 
frontal processing areas being suggested as a potential mechanism for these 
impairments (Heffernan et al, 2001; Rendell et al, 2007; Hadjiefthyvoulou et al, 
2011a,b; Parrott, 2013b).  MDMA is a selective serotonin neurotoxin in laboratory 
animals, and neuroimaging studies have found reduced SERT levels in humans, 
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although there is active debate over the underlying nature of these serotonergic 
changes (Kish et al, 2010; Di Iorio et al, 2012; Benningfield and Cowan, 2013; 
Parrott, 2013b). In this context, Quelch et al (2012) is particularly relevant for debating 
how to interpret the many SERT imaging studies which have used the ligand DASB.  
 
Given the reductions in SERT density in the cerebral cortex, it would be expected that 
the neurocognitive functions subserved by these 5-HT rich areas should also show a 
decline. Areas of the dorsolateral prefrontal cortex are densely innervated bywith 5-
HT neurons, and they are understood to belie executive functioning ability (Curtis and 
D’Esposito, 2003). Many studies have investigated executive functioning in 
ecstasy/MDMA users, although again the performance findings have been quite 
varied (Murphy et al, 2009). One potential reason for this inconsistency may be that 
the tasks used in these earlier studies were not function specific. Miyake et al (2000) 
proposed that overall executive functioning comprised three correlated, but distinct, 
sub-functions:  updating, switching, and inhibitory control, while a fourth 
subcomponent of access to semantic/long term memory was added by Fisk and Sharp 
(2004). In a systematic review and meta-analysis of executive performance in ecstasy 
users versus polydrug controls, it was concluded that ecstasy users showed 
performance deficits in updating, switching and access, but not in inhibitory control 
(Roberts et al’., 2016b). This is particularly interesting, given that a more recent 
theoretical framework of executive functioning  suggestedfunctioning suggested that 
inhibitory control might not be an independent factor (Miyake et al, 2012). Mention 
should also be made of Halpern et al (2011), since this study has often been cited as  
finding no cognitive deficits in Ecstasy/MDMA users. Indeed their Abstract suggested 
only slight deficits: ‘We found little evidence of decreased cognitive performance in ecstasy 
users, save for poorer strategic self-regulation’, althought they also noted: ‘This finding 
contrasts with many previous findings including our own’, However close examination shows 
that there were significant performance deficits on several cognitive measures; these 
were debated in the following commentaries (Fisk et al, 2011; Parrott,  2011; Rodgers 
et al, 2011).      
 
Recent neuroimaging studies have increased our understanding of how MDMA may 
alter cognitive function. Using function specific tasks, Roberts and Montgomery 
(2015a,b) observed changes in neuronal activation in Ecstasy/MDMA users compared 
to non-users, whilst completing tasks that tap access and inhibitory control. In each 
case, the findings suggested that ecstasy users were engaged in more effortful 
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cognition, indexed by increases in oxygenated haemoglobin, to those brain sites 
needed for cognitive performance. It is proposed that this extra effort allowed them to 
reach the performance levels achieved by the controls. The authors concluded that 
these changes in haemodynamics may reflect serotonergic neuroadaptation from 
repeated Ecstasy/MDMA use. These findings also highlighted the greater sensitivity 
of neuroimaging measures for detecting cognitive changes, when compared to 
behavioural measures alone. These studies were conducted using functional near-
infrared spectroscopy (fNIRS). This is a relatively low cost neuroimaging technique, 
which measures changes in oxygenated and deoxygenated haemoglobin within the 
pre-frontal cortex. It measures near-infrared light at two wavelengths, one of which is 
attenuated by oxygenated haemoglobin, while the other is attenuated by deoxygenated 
haemoglobin. This can measure changes in haemodynamics to areas of the pre frontal 
cortex involved in many higher order cognitive tasks. This imaging technique is also 
robust to movement artefacts, so that it can be used with cognitive tasks requiring 
vocalisations or limb movements. The utility of fNIRS for future research has recently 
increased with whole head fNIRS systems, especially since they can be used 
simultaneously with EEG for multi-modal neural signalling. This may enable future 
research to elucidate MDMA effects on brain haemodynamics and electrophysiology, 
in relation to a wide range of cognitive functions. The contributory role of the 
serotonin system should also be monitored, since it displays modulatory effects for 
many different aspects of neurocognition (Meneses, 1999; Schmitt et al, 2006; Švob-
Štrac et al, 2016) 
 
Vision. 
 
The visual cortex also receives serotonergic input from the raphe nuclei, and due the 
long axon distances, it appears to be particularly vulnerable to ecstasy-mediated 
alterations (Roberts et al. 2016a). In a series of studies utilising responses to visual 
illusions, impairments in some aspects of visual processing have been demonstrated 
among abstinent ecstasy consumers. For instance, they have demonstrated 
compromised orientation processing of stimuli at the level of the primary visual 
cortex or V1 (Dickson et al, 2009). These visual changes were positively correlated 
with the frequency and quantity of ecstasy use, but were independent of other drugs 
consumed. Subsequent studies from another laboratory have replicated this 
Formatted: Font: (Default) Times New Roman, 12 pt
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impairment, and demonstrated that the underlying mechanism may reflect a 
serotonergic role in lateral inhibitory processes in orientation sensitive neurons (White 
et al, 2013). However, such orientation processing deficits are not apparent in 
response to stimuli primarily processed in prestriate cortex V2 (Murray et al, 2012); 
this may possibly arise from the pooling of orientation signals as the information is 
being processed at higher levels of the visual cortex.  
 
Using apparent global motion paradigms, Hall (2010) demonstrated pronounced 
motion processing deficits, as indicted by higher global motion thresholds; these 
visual deficits were related to Ecstasy/MDMA consumption, but were independent of 
other drugs including cannabis. Complex motion processing deficits among abstinent 
ecstasy consumers have also been identified by others (Rizzo et al, 2005). This work 
directly contradicts another small scale study using a similar paradigm that has 
suggested improved motion processing - albeit only in a subset of consumers (White 
et al, 2014). These effects on basic visual functioning have the potential to contribute 
to impairments in daily activities reliant on these processes, such as driving. In acute 
dosing studies, MDMA has been observed to impair various aspects of driving ability, 
including overall driving performance, and signalling adherence (Stough et al, 2012); 
these studies need to be repeated with chronic users. Furthermore it also changes other 
aspects of ocular activity, with increasing nystagmus (Downey et al, 2012), and 
driving problems such as tailgating are more apparent in abstinent Ecstasy/MDMA 
consumers (Dastrup et al, 2010). RAlthough recent studies in our laboratory have 
failed to identify any deficits among abstinent ecstasy consumers on motion 
processing tasks in the context of simulated driving, such as estimation of time to 
collision with oncoming traffic (Bernard, 2011). This suggests that any impairment in 
coarse behavioural tasks such as driving, may not simply be a reflection of impaired 
visual processing. For instance, heightened levels of impulsivity have also been 
found, and this may be a contributing factor (Quednow et al, 2007). There may also 
be some differences in visual scanning of the overall driving environment. Alterations 
in visual perception and attention as indicated by saccadic eye movement patterns 
may provide an indicator of how changes in visual scanning behaviour contribute to 
an increase in the risk of accidents in abstinent MDMA users. Future research 
concerning the on-road and simulated driving ability of Ecstasy/MDMA users, both 
on drug and drug free, could benefit from inclusion of saccadic eye movement 
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technology to provide an index of more basic visual abilities and their putative 
disruption.  
 
Polydrug factors. 
 
Recreational Ecstasy/MDMA users often take a range of other psychoactive drugs, so an 
important issue is the neuropsychological consequences of this polydrug usage. In order to 
partially address this factor, most studies employ a comparison group of polydrug users who 
have taken other illicit recreational drugs, but not Ecstasy/MDMA (Fox et al, 2001; Fisk et al, 
2005; Singer et al, 2016). Some studies employ two comparison groups: polydrug/illicit drug 
users, and legal drug-users (Hadjiefthyvoulou, et al, 2011a; Roberts and Montgomery, 
2016b), while others have employed multiple comparison groups. For instance, Parrott et al 
(2001) compared 768 young volunteers divided into six subgroups: non-users of any 
psychoactive drug (n=150); alcohol and/or tobacco (n=185); cannabis and alcohol/nicotine 
(n=97); non-MDMA polydrug (n=102);  light Ecstasy/MDMA polydrug (n=115); and heavy 
Ecstasy/MDMA polydrug users (n=119). Self-rated psychiatric problems increased in line 
with greater psychoactive drug usage. The large sample sizes also facilitated the attribution of 
specific problems to particular drugs, with the Ecstasy/MDMA findings outlined in Milani et 
al (2000). Taurah et al (2013) assessed 997 participants divided into six subgroups: no 
psychoactive drugs (n=182);  alcohol; alcohol and nicotine (n=172); cannabis, alcohol and 
nicotine (n=163) ; non-MDMA polydrug (n=169); current MDMA polydrug (n=154); and 
former MDMA polydrug (n=157). They found significant impairments in both subgroups of 
Ecstasy/MDMA polydrug users across the whole of their test battery - which covered four 
psychobiological functions (sleep, impulsiveness, depression, and memory). The former 
Ecstasy/MDMA users showed minimal signs of functional recovery, despite nearly 5- years 
of abstinence. The large sample size also allowed the psychobiological effects of other drugs 
to be both analysed by regression, and statistically controlled via covariance. Taurah et al 
(2013) found that alcohol, cannabis, cocaine and ketamine were each associated with some 
psychobiological deficits, with moderate-to-high beta values.  Furthermore, when alcohol, 
amphetamine, cannabis, cocaine, heroin, and ketamine were entered as co-variants, the 
deficits attributable to Ecstasy/MDMA remained significant - in both the current and former 
users.   
 
Some studies have compared low and high Ecstasy/MDMA user subgroups, while others have 
statistically investigated the associations between specific performance deficits and individual 
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drugs, in order to investigate this polydrug factor (Fox et al, 2001; Rodgers et al, 2003). None 
of these approaches are however ideal, since the heavier Ecstasy/MDMA users are often more 
experienced users of other drugs (see Table 1 in Parrott et al, 2001). Hence despite the 
employment of polydrug users as controls, and statistical procedures such as regression and 
covariance, none of the current approaches provide a full solution. In methodological terms, 
recreational drugs research will always be quasi-experimental. Laboratory animal research 
can be relevant and useful, since it allows full empirical control, with placebo conditions and 
random drug allocation. Meta-analyses and theoretical debates around ‘construct validity’ are 
also crucial for our critical awareness and conceptual understanding (Parrott, 1991, 2013b; 
Laws and Kokkalis, 2007; Rogers et al, 2009). It should be noted that Ecstasy/MDMA 
research has been at the forefront of this complex issue. It was noted in most of the early 
reviews, and an early theoretical debate (Parrott, 2004), had been followed by a more 
extensive and comprehensive review (Mohamed et al, 2011). Nearly every paper in this field 
currently refers to Ecstasy/MDMA ‘polydrug’ users. This is far less apparent in other fields of 
recreational drug research, such as cannabis, nicotine, cocaine or amphetamine (Parrott, 
2015). Hence multiple-drug-usage remains a pervasive problem across the whole field of 
recreational drugs research. For the future, more creative and sophisticated solutions need to 
be devised, perhaps incorporating molecular imaging, pharmacological challenges and genetic 
research methodologies, and well designed prospective studies.       
nNoften more.Hence multiple, perhaps incorporating molecular imaging, pharmacological 
challenges and genetic research methodologies, with well-designed prospective studies 
 
 
Human pregnancy and foetal aspects 
 
Psychoactive drugs can impair foetal development, and deficits have been found with 
alcohol, cocaine, nicotine, heroin, cannabis, and many other drugs (Minnes et al, 
2011; Behnke et al, 2013). The devastating effects of methyl mercury poisoning in the 
1950s, and thalidomide in the 1960s, showed the profound foetal vulnerability to all 
toxins - even at low or negligible doses. Hence it is important to empirically 
investigate the neurobehavioral effects of prenatal Ecstasy/MDMA exposure on infant 
development. The pharmacodynamic effects of acute Ecstasy include changes to the 
5-HT system, the HPA axis and gonadal hormones (Dickerson et al., 2008; Parrott et 
al., 2014), and all these factors may be linked to reductions in prenatal growth and 
postnatal development (Davis et al, 2011, Boukhris et al, 2016). The neuroadaptations 
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with MDMA have also been associated with fluctuations in mood, cognition, sleep, 
and appetite (Curran and Travill, 1997; Parrott, 2002),  additional factors which may 
also impact on foetal development (Okun et al, 2013, Kinsella and Monk, 2009).  In 
recent years, women of child-bearing age have been consuming drugs such as Ecstasy 
to similar extents as men (Degenhardt et al, 2008), setting them at a sex-specific 
disadvantage for secondary risk factors such as psychiatric co-morbidity (Fox and 
Sinha, 2009).  
 
The DAISY study recruited women who used Ecstasy and/or other recreational drugs 
at any time during their pregnancy, and prospectively assessed the neuropsychological 
development of their infants at various time points post-partum (Singer et al, 2012a,b, 
2016). The pregnant women were categorised into three groups dependent upon their 
Ecstasy/MDMA usage during pregnancy: heavy Ecstasy users (n=13; 1.7 ± 1.8 tablets 
per week), light Ecstasy users (n=12; 0.09 ± 0.06 tablets per week), and polydrug user 
controls (n=68). The groups were statistically matched for a range of salient 
individual, drug and environmental factors. The Ecstasy/MDMA using mothers had 
used more cannabis, so this was employed as a co-variate. These women were 
predominantly from middle class backgrounds, living with partners, receiving similar 
annual incomes, similarly educated and showed no variation in terms of psychological 
profiles, or drug dependence.  
 
Physical differences in foetal development were not observed, although at 1 month the 
Ecstasy-exposed infants were somewhat more lethargic and less hypertonic. At 4 
months, the heavily Ecstasy-exposed infants performed significantly worse on gross 
motor skills as measured by the Alberta Infant Motor Scale (Piper et al, 1992), and 
Bayley Behavioral Rating Scales (Bayley, 1993). At 12 months post-partum these 
psychomotor decrements were again more severe in the heavily-exposed Ecstasy 
group compare to controls, and they persisted at two years of age, when the study 
ended (Singer et al, 2016). The lightly exposed Ecstasy babies were not impaired at 
any time point, although their very low levels of maternal Ecstasy exposure should be 
noted. One of the babies in the heavy exposure group showed severe birth defects, 
consistent with earlier case study reports of birth defects in MDMA exposed infants 
(McElhatton et al, 1999). These decrements in motor development may impact on 
later social relationships, thinking, and language. Gross motor development allows 
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infants to explore their environment, while fine motor skills represent the beginnings 
of object-based play and tool use which facilitate pre-verbal communication. 
Consequently, while language-related deficits were not observed in the DAISY study, 
social communication and interpersonal issues may possibly arise at later 
developmental stages (Chaibal et al, 2016). In terms of future research, our main 
recommendation is for an extended and prolonged replication. It would assess a larger 
numbers of ecstasy/MDMA exposed women, with the infants tested beyond 2 years, 
non-drug controls in addition to the polydrug controls, a larger battery of 
neurohormonal measures (e.g. cortisol, oxytocin, prolactin; Parrott, in press), and 
indices of serotonergic integrity.  
 
Potential causes for the psychobiological variation  
 
This final section will debate possible causes for the variance in findings, and suggest 
some future research topics.  The most crucial factor is probably the amount of drug 
taken, indeed the contributory the role of lifetime usage has often been noted 
(Gouzoulis-Mayfrank et al, 2003; Parrott, 2006; Kish et al, 2010; White, 2014). Other 
potentially important drug factors might be the amount taken at any one session, 
drugits purity, and method of administration the mode of drug delivery. These are 
more difficult to measure since they are inherently more variable, and may change 
with greater experience. Indeed they may be closely related to lifetime usage, with 
chronic tolerance leading to more intensive usage (Parrott, 2005). Tablets have been 
the traditional vehicleroute for self-administration, but in recent years they have been 
complemented by ‘bombs’ (MDMA powders wrapped in Rizla papers and 
swallowed), and nasal insufflation (snorting as in cocaine). The functional 
implications of these newer, and potentially stronger methods of self-administration, 
need to be empirically investigated. Such methodsince they facilitate higher self-
dosing, thusey may be related to stronger outcomes. Very heavy users may also inject, 
but again the practical implications have rarely been studied. Samuel et al (2013;  full 
report Downey et al, in press).  ) reported found significant deficits in gross 
psychomotor skill in drug free drug-free MDMA polydrug injectors, but this finding 
needs to be empirically replicated..   
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Environmental factors when on drug are also important, especially the physical and 
psychosocial conditions during consumption. Ambient and core body temperature, 
crowding, prolonged dancing and loud music can combine to produce hyper-
stimulation, potentially through the integrative actions of the HPA axis.  The master 
neurohormone for the HPA axis is cortisol, and this is increased significantly by 
MDMA in the laboratory, while the degree of cortisol increase can be dramatically 
higher, around 800%, when MDMA is taken at clubs (Parrott et al, 2008). Three-
month hair samples revealed that regular Ecstasy/MDMA users have cumulative 
cortisol levels 400% higher than non-user controls (Parrott et al, 2014). Cortisol 
provides a simple biological index for the level of energetic stress experienced by the 
organism; hence it may provide a useful measure for future research. In particular, it 
could be employed to test the bio-energetic stress model for humans (Parrott, 2006). 
This model is closely based on laboratory animal data which shows a wide range of 
environmental and drug interactions (Huether et al, 1997). The model proposes that 
the extent of bioenergetic stress experienced by the organism, will determine the 
degree of psychobiological problems it develops.  
 
Another important neurohormone is oxytocin, since it is involved in affiliative 
behaviours, and may be central for the pro-social effects of recreational 
Ecstasy/MDMA (McGregor et al, 2008; Broadbear et al, 2014). However, again the 
empirical findings are surprisingly variable. While one empirical study found a 
positive correlation between the extent of oxytocin release and pro-social outcomes in 
terms of moods (Dumont et al, 2009), several other studies failed to demonstrate the 
predicted association (Parrott, 2016in press). Future research might benefit from 
investigating a wider range of psychobiological dependent variables. Could  
differencesPerhapsCould differences in oxytocin reactivity could help to explain some 
of the variation in mood reactions to MDMA?. Similarly oOxytocin may also account 
for the increased libido, and riskier sexual behaviours, of some recreational MDMA 
users (Theall et al, 2006; May and Parrott, 2015). It may also be important during 
pregnancy, given its core functions around birth (viz: for birth contractions and 
subsequent lactation). Hence it would be interesting to replicate the prospective 
DAISY study (Singer et al, 2012a,b, 2016), using a full battery of neurohormonal 
measures administered at various time points during pregnancy, and after the birth.  
Another important group of factors are individual differences, since they may 
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contribute to the variation in research outcomes. Individual differences in personality 
and psychiatric wellbeing have been investigated with many types of psychoactive 
drug, including alcohol, nicotine, cannabis, and the opiates. Yet surprisingly they have 
not featured strongly in MDMA research, despite potentially helping to explain why 
some individuals may be more far susceptible to the development of 
neuropsychobiological problems than others.  Genetic factors have also been 
investigated in a few studies, but again they need to be monitored more widely.  
 
In summary, MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy remains a 
popular illicit drug, despite the many long-term negative consequences associated 
with repeated use. Moreover recreational use is a continued public health concern, 
particularly given recent increases in MDMA-related deaths (Anderson, 2014), and 
increasing tablet strength (Global Drugs Survey; Winstock, 2015), which reported 
tablets containing up to 200mg MDMA. With these higher strength supplies, the 
repeated use of MDMA may adversely affect the 5HT system after fewer lifetime 
exposures, than shown in earlier studies (Kish et al, 2010; Erritzoe  et al, 2011; 
others). In a recent review of the psychobiological problems associated with these 
serotonergic changes,  evident in regular MDMA users (e.g. Kish et al, 2010), it was 
clear that a wide range of psychobiological functions could be impaired (Parrott, 
2013b). Yet these deficits could often be quite subtle, agreeing with the conclusion 
offered by Jacobs and Furnell (1997) that: ‘Serotonin is an enigma, it is involved in 
everything, but responsible for nothing’. The psychological deficits apparent in many 
recreational users fit this model. Hence we urge future research to be theoretically 
driven, and empirically test potential explanations - such as the energetic stress model. 
Certainly any explanatory model will need to consider a range of drug and non-drug 
factors as potential causative agents. The research might also help elucidate the 
diverse psychobiological functions subserved by serotonergic neurotransmission, and 
their potential modulation by neurohormonal influences.     
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